12.18.09
Patheon
4Q Revenues: $176.1 million (+2%)
4Q Earnings: $4.6 million (-88%)
FY Revenues: $655.1 million (-9%)
FY Loss: $6.8 million (earnings of $0.8 million in FY08)
Comments: Commercial manufacturing revenues were up 6% to $144.2 million in 4Q09, but dropped 8% for FY09 to $530.0 million. Pharmaceutical Development Services (PDS) revenues dropped 13% in 4Q09, reflecting cutbacks in development throughout the industry. For FY09, PDS revenues dropped 10% to $125.1 million. During 4Q09, the company announced plans to consolidate its operations and Puerto Rico. Also in 4Q09, the company's Special Committee and Jll Partners, its primary shareholder, reached a settlement over their contentious ownership dispute.
4Q Revenues: $176.1 million (+2%)
4Q Earnings: $4.6 million (-88%)
FY Revenues: $655.1 million (-9%)
FY Loss: $6.8 million (earnings of $0.8 million in FY08)
Comments: Commercial manufacturing revenues were up 6% to $144.2 million in 4Q09, but dropped 8% for FY09 to $530.0 million. Pharmaceutical Development Services (PDS) revenues dropped 13% in 4Q09, reflecting cutbacks in development throughout the industry. For FY09, PDS revenues dropped 10% to $125.1 million. During 4Q09, the company announced plans to consolidate its operations and Puerto Rico. Also in 4Q09, the company's Special Committee and Jll Partners, its primary shareholder, reached a settlement over their contentious ownership dispute.
